These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 36332438)
21. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome. Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T Front Immunol; 2021; 12():651086. PubMed ID: 34248939 [TBL] [Abstract][Full Text] [Related]
22. Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. Tétu P; Sirven-Villaros L; Cuzzubbo S; Ursu R; Baroudjian B; Delyon J; Nataf F; De Margerie-Mellon C; Allayous C; Lefevre W; Carpentier AF; Lebbé C Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947841 [TBL] [Abstract][Full Text] [Related]
23. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy- Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L Front Oncol; 2021; 11():639085. PubMed ID: 34094921 [No Abstract] [Full Text] [Related]
24. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577 [TBL] [Abstract][Full Text] [Related]
25. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059 [TBL] [Abstract][Full Text] [Related]
26. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Pires da Silva I; Ahmed T; McQuade JL; Nebhan CA; Park JJ; Versluis JM; Serra-Bellver P; Khan Y; Slattery T; Oberoi HK; Ugurel S; Haydu LE; Herbst R; Utikal J; Pföhler C; Terheyden P; Weichenthal M; Gutzmer R; Mohr P; Rai R; Smith JL; Scolyer RA; Arance AM; Pickering L; Larkin J; Lorigan P; Blank CU; Schadendorf D; Davies MA; Carlino MS; Johnson DB; Long GV; Lo SN; Menzies AM J Clin Oncol; 2022 Apr; 40(10):1068-1080. PubMed ID: 35143285 [TBL] [Abstract][Full Text] [Related]
27. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907 [TBL] [Abstract][Full Text] [Related]
28. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study. Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145 [TBL] [Abstract][Full Text] [Related]
29. Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. Dercle L; Zhao B; Gönen M; Moskowitz CS; Firas A; Beylergil V; Connors DE; Yang H; Lu L; Fojo T; Carvajal R; Karovic S; Maitland ML; Goldmacher GV; Oxnard GR; Postow MA; Schwartz LH JAMA Oncol; 2022 Mar; 8(3):385-392. PubMed ID: 35050320 [TBL] [Abstract][Full Text] [Related]
30. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825 [TBL] [Abstract][Full Text] [Related]
31. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis. Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y Front Immunol; 2022; 13():1083840. PubMed ID: 36618343 [TBL] [Abstract][Full Text] [Related]
32. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L Front Immunol; 2021; 12():691032. PubMed ID: 34290710 [TBL] [Abstract][Full Text] [Related]
33. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599 [TBL] [Abstract][Full Text] [Related]
34. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Geukes Foppen MH; Brandsma D; Blank CU; van Thienen JV; Haanen JB; Boogerd W Ann Oncol; 2016 Jun; 27(6):1138-1142. PubMed ID: 26961150 [TBL] [Abstract][Full Text] [Related]
35. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137 [TBL] [Abstract][Full Text] [Related]
36. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience. Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Zhang Y; Liu B; Kotenko S; Li W Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066 [TBL] [Abstract][Full Text] [Related]
38. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis. Xu J; Zhao J; Wang J; Sun C; Zhu X Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Rozeman EA; Versluis JM; Moritz R; Wilgenhof S; van Thienen JV; Haanen JBAG; van de Heuvel MM; Blank CU; van Rossum HH Clin Chim Acta; 2022 Aug; 533():71-78. PubMed ID: 35709988 [TBL] [Abstract][Full Text] [Related]
40. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]